{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:12:16Z","timestamp":1775470336435,"version":"3.50.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>Calcinosis is an intractable condition in juvenile dermatomyositis (JDM). The effect of abatacept on calcinosis remains controversial. We describe a case of an 8-year-old boy in whom the addition of abatacept to mycophenolate mofetil was effective against calcinosis in JDM. The patient with antinuclear matrix protein 2 autoantibody suffered from refractory jJDM despite long-term treatment with corticosteroids and various immunosuppressive agents. Subcutaneous calcinosis with repeated spontaneous pain at the calcinosis site emerged 2\u2009years after the start of treatment and gradually increased despite clinical improvement in muscle symptoms. The addition of intravenous abatacept to mycophenolate mofetil at the age of 6 years halted the increase in calcinosis. Spontaneous pain in calcinosis disappeared within 2\u2009months. The calcinosis had significantly decreased by 1\u2009year. An important strategy on calcinosis in JDM is getting complete control of the inflammation. Our case report suggests that abatacept may contribute to the improvement of calcinosis in JDM, at least as part of combination therapy with mycophenolate mofetil.<\/jats:p>","DOI":"10.1093\/mrcr\/rxaf004","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:20:39Z","timestamp":1741652439000},"source":"Crossref","is-referenced-by-count":2,"title":["Effect of abatacept added to mycophenolate mofetil for refractory calcinosis in juvenile dermatomyositis"],"prefix":"10.1093","volume":"9","author":[{"given":"Maho","family":"Shimizu","sequence":"first","affiliation":[{"name":"Department of Infection and Immunology, Allergy and Immunology Center, Aichi Children\u2019s Health and Medical Center , Obu, Aichi,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruna","family":"Nakaseko","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Allergy and Immunology Center, Aichi Children\u2019s Health and Medical Center , Obu, Aichi,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2329-8375","authenticated-orcid":false,"given":"Yoshinao","family":"Muro","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Nagoya University Graduate School of Medicine , Nagoya, Aichi,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6149-1358","authenticated-orcid":false,"given":"Naomi","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Allergy and Immunology Center, Aichi Children\u2019s Health and Medical Center , Obu, Aichi,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"2025080201022077400_R1","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/joim.12444","article-title":"The juvenile idiopathic inflammatory myopathies: pathogenesis, clinical and autoantibody phenotypes, and outcomes","volume":"280","author":"Rider","year":"2016","journal-title":"J Intern Med"},{"key":"2025080201022077400_R2","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-020-00974-9","article-title":"Treatment of calcinosis in juvenile dermatomyositis","volume":"23","author":"Kul Cinar","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"2025080201022077400_R3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jaad.2019.07.006","article-title":"Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: a review of the literature","volume":"82","author":"Traineau","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025080201022077400_R4","article-title":"Calcinosis in juvenile dermatomyositis: updates on pathogenesis and treatment","volume":"10","author":"Pinotti","year":"2023","journal-title":"Front Med Lausanne"},{"key":"2025080201022077400_R5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/art.42450","article-title":"Improvement in disease activity in refractory juvenile dermatomyositis following abatacept therapy","volume":"75","author":"Curiel","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2025080201022077400_R6","article-title":"Abatacept in the treatment of juvenile dermatomyositis-associated calcifications in a 16-year-old girl","volume":"2020","author":"Sukumaran","year":"2020","journal-title":"Case Rep Rheumatol"},{"key":"2025080201022077400_R7","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jpeds.2011.11.057","article-title":"Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis","volume":"160","author":"Arabshahi","year":"2012","journal-title":"J Pediatr"},{"key":"2025080201022077400_R8","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1093\/rheumatology\/kes033","article-title":"Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2","volume":"51","author":"Ishikawa","year":"2012","journal-title":"Rheumatology"},{"key":"2025080201022077400_R9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1006\/clim.1999.4743","article-title":"Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells","volume":"92","author":"Nagaraju","year":"1999","journal-title":"Clin Immunol"},{"key":"2025080201022077400_R10","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1136\/annrheumdis-2017-211751","article-title":"Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial","volume":"77","author":"Tj\u00e4rnlund","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025080201022077400_R11","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3899\/jrheum.211393","article-title":"Management of calcinosis cutis in rheumatic diseases","volume":"49","author":"Elahmar","year":"2022","journal-title":"J Rheumatol"},{"key":"2025080201022077400_R12","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102533","article-title":"Calcinosis biomarkers in adult and juvenile dermatomyositis","volume":"19","author":"Chung","year":"2020","journal-title":"Autoimmune Rev"},{"key":"2025080201022077400_R13","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/BOR.0b013e32834ff5cd","article-title":"Soft tissue and subcutaneous calcification in connective tissue diseases","volume":"24","author":"Chander","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"2025080201022077400_R14","doi-asserted-by":"crossref","DOI":"10.1186\/ar2865","article-title":"CTLA4-Ig interacts with cultured synovial macrophages from rheumatoid arthritis patients and downregulates cytokine production","volume":"11","author":"Cutolo","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2025080201022077400_R15","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/BOR.0000000000000491","article-title":"How does abatacept really work in rheumatoid arthritis?","volume":"30","author":"Bonelli","year":"2018","journal-title":"Curr Opin Rheumatol"},{"key":"2025080201022077400_R16","doi-asserted-by":"crossref","first-page":"786","DOI":"10.3899\/jrheum.141288","article-title":"Longterm efficacy and safety of abatacept in patients with rheumatoid arthritis treated in routine clinical practice: effect of concomitant methotrexate after 24 weeks","volume":"42","author":"Takahashi","year":"2015","journal-title":"J Rheumatol"},{"key":"2025080201022077400_R17","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1002\/art.39234","article-title":"Long-term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years","volume":"67","author":"Lovell","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2025080201022077400_R18","doi-asserted-by":"crossref","DOI":"10.1186\/s12969-019-0319-4","article-title":"Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study","volume":"17","author":"Hara","year":"2019","journal-title":"Pediatr Rheumatol Online J"},{"key":"2025080201022077400_R19","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101425","article-title":"Risk of hepatitis B virus reactivation following treatment with abatacept: a retrospective study of international pharmacovigilance databases","volume":"48","author":"Wang","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2025080201022077400_R20","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/856815","article-title":"A new ELISA for dermatomyositis autoantibodies: rapid introduction of autoantigen cDNA to recombinant assays for autoantibody measurement","volume":"2013","author":"Muro","year":"2013","journal-title":"Clin Dev Immunol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxaf004\/62385551\/rxaf004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf004\/62385551\/rxaf004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf004\/62385551\/rxaf004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T05:02:30Z","timestamp":1754110950000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxaf004\/8071617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxaf004","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rxaf004"}}